KEY POINTS
  • Solanezumab's failure is a blow to efforts to treat Alzheimer's in people who are in the very early stage of the disease and have not yet shown clinical symptoms.
  • Solanezumab did not clear or halt accumulation of brain plaque and did not slow cognitive decline in the participants who received the treatment.
  • Lilly is developing two other Alzheimer's treatments that are in late-stage clinical trials, donanemab and remternetug.

In this article

The Eli Lilly logo is shown on one of the company's offices in San Diego, California, Sept. 17, 2020.

Eli Lilly on Wednesday said it will halt development of its Alzheimer's treatment candidate solanezumab after the antibody failed to slow disease progression.

Solanezumab's failure is a blow to efforts to treat Alzheimer's in people who are in the very early stage of the disease and have not yet shown clinical symptoms.

In this article